The EPS decline likely left investors hesitant, as Sino Biop...

The EPS decline likely left investors hesitant, as Sino Biopharmaceutical's performance, with a 34% loss including dividends, underperformed the broader market's 16% loss. This may signal unresolved challenges, given it's worse than the 6% annualised loss over the last half decade.